Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
about
Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating AspirinCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsThe antithrombotic profile of aspirin. Aspirin resistance, or simply failure?Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general populationBenefit-Risk Assessment of Fish Oil in Preventing Cardiovascular DiseaseNew insights into the use of currently available non-steroidal anti-inflammatory drugsPlatelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery diseaseMass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseaseCyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outsAntiplatelet drugsDifferential impact of prostaglandin H synthase 1 knockdown on platelets and parturition.Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsSelenium Micronutrient NetworkVitamin B12 MetabolismFolate MetabolismClinical Pharmacology and Cardiovascular Safety of NaproxenVascular COX-2 modulates blood pressure and thrombosis in mice.Prostanoid receptor antagonists: development strategies and therapeutic applicationsA Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirinHyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirinBiological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance.Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs.Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyAntiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesEffect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.Brain changes associated with thromboxane receptor antagonist SQ 29,548 treatment in a mouse modelA comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular riskDrug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy.Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.
P2860
Q22306342-B5F502A1-CE0B-434B-9E0C-92A74A3A96A1Q24555072-05EC66EE-AF61-4C41-AB87-E59F26CBB290Q24794673-2F674CFE-B4D3-46AC-B7C1-93DEDB15C4C6Q24816136-05412B38-F279-4982-BA9A-B6D733996AC0Q26740486-29BFA3E4-5641-4870-AF22-952713135009Q26852330-1711E857-4CF1-4C6D-B112-2627C447E696Q27027247-6F1709F9-7460-45C9-827D-F923DD7ACC4EQ28075372-457504B6-F6C5-4768-88A3-8526663452C1Q28186050-1BE4DBC1-FB99-4030-A12D-304081D96354Q28194430-E5523457-5C39-4ECF-B0D2-DC532DF5A5C8Q28210819-19085F7F-60B8-4522-A024-EAACD2E70B5DQ28211940-95F5F341-561B-4924-8D06-F58F121B8CEDQ30225370-DD5BBFA7-0887-4D0D-A5C5-35D603ACD898Q30225376-829B6B9F-2148-4D0B-8193-ECE0A577251BQ30225387-49D38B7B-9348-4A8E-8B3B-36185819E2C0Q30360728-53E49398-3647-4C35-B178-C75698C5898AQ30562262-D65FAB76-7708-4B6C-836B-205B7DA21264Q33485483-D800979D-1FB1-4C6C-8C5D-0EAEEF0C0204Q33629231-04C96CB1-F86B-404C-89BF-4C9A99291FA4Q33837587-92666761-09E8-4BDE-B821-DF205DBBB003Q33873092-E7B8FFB8-C27C-4F7D-80E1-2724BB4B30DEQ33952053-29073C8F-9EE6-4CA2-B4B0-5F5C4904E08CQ34245387-D6A9CE4E-D745-4D0A-9C3D-8F56C0DA44AEQ34249714-BA48BCD2-F30F-41B7-AD01-51CAB30A304AQ34357514-2BFD1863-394D-4223-882E-9A763FFE5A0AQ34371114-C00E42DA-23E1-4081-9225-EF5E58BF9A0AQ34536091-8AFFEC03-CE2C-438A-A399-FE926075513EQ34601141-11B422E5-9C1B-4A06-99A5-9B0EFAB3BB1EQ34730034-7B453A24-0C92-48E9-897B-790EED1E929AQ34803113-524D43B7-F6A2-452F-B0C6-8A1E89ADD501Q35373624-AC5759B5-CEE1-4D5B-B53D-6CD52B9BEB61Q35752619-97803B60-4597-4220-BA61-810BB91CBE63Q35769055-206124E6-F39E-4161-AF34-1327FB02E219Q35772240-CED9A166-B02B-472E-B042-E579494E8116Q35803781-5F7F6B8C-7456-4A1C-8C70-C59C018ECE63Q35899381-E84CC75A-D7AC-4878-A1E3-CDD15E2CAC32Q36104404-5F697B5E-B407-4D63-9947-E63B8A40663FQ36163277-C558192A-AFC1-43F4-8F87-789D47F50900Q36329991-7518CA2F-9F7F-4867-A07F-9CD2DFFFDCF2Q36802113-7649858D-879B-47A7-84F9-25CD6E5F5164
P2860
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
description
1987 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1987
@ast
im Januar 1987 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1987/01/01)
@sk
vědecký článek publikovaný v roce 1987
@cs
wetenschappelijk artikel (gepubliceerd op 1987/01/01)
@nl
наукова стаття, опублікована в січні 1987
@uk
مقالة علمية (نشرت عام 1987)
@ar
name
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@ast
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@en
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@nl
type
label
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@ast
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@en
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@nl
prefLabel
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@ast
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@en
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@nl
P3181
P1433
P1476
Inhibition of thromboxane form ...... with platelet inhibitory drugs
@en
P2093
G. A. FitzGerald
I. A. Reilly
P304
P3181
P407
P577
1987-01-01T00:00:00Z